Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications - reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study

This is an accepted manuscript of an article published by Wiley in Alimentary Pharmacology and Therapeutics, available online at: https://doi.org/10.1111/apt.16349 The accepted version of the publication may differ from the final published version.